Q1 2025 Royalty Pharma PLC Earnings Call Transcript
Key Points
- Royalty Pharma PLC (RPRX) reported a 12% growth in Royalty receipts, reflecting the strength of its diversified portfolio.
- The company announced a new Phase III R&D funding collaboration with Biogen for litifilimab in lupus, a potential blockbuster therapy.
- Royalty Pharma PLC (RPRX) raised its 2025 full-year guidance, expecting portfolio receipts between $2.975 billion and $3.125 billion.
- The company repurchased $723 million of its shares in the first quarter, part of a plan to repurchase up to $2 billion in 2025.
- Royalty Pharma PLC (RPRX) maintained significant financial capacity with cash and equivalents of close to $1.1 billion and an upgraded credit rating from Moody's.
- The company faces policy uncertainties that could impact the deal-making environment, although it has not yet affected their opportunity set.
- There is no update on the arbitration timelines for the Vertex cystic fibrosis portfolio negotiations.
- The company incurred $33 million of one-time payments related to the sales of the MorphoSys development funding bonds.
- Interest paid in the first quarter was $127 million, reflecting the semiannual timing of interest payments and new debt raised in 2024.
- The company is operating in an environment with potential tariffs, although it does not expect a meaningful impact on its royalties.
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma first quarter earnings conference call. I would now like to turn the call over to George Grofik, Senior Vice President and Head of Investor Relations and Communications.
Please go ahead, sir.
Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's first quarter 2025 results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com.
Moving to slide 3. I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from statements.
We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
